Literature DB >> 7663787

Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression.

J Berenguer1, M C Allende, J W Lee, K Garrett, C Lyman, N M Ali, J Bacher, P A Pizzo, T J Walsh.   

Abstract

Patients with chemotherapy-induced granulocytopenia for neoplastic diseases and those receiving cyclosporin A plus corticosteroids for prevention and treatment of organ transplant rejection are two immunologically distinct patient populations with high risks for development of invasive pulmonary aspergillosis. In order to compare the pathogenesis of aspergillosis in these two high-risk populations and to further characterize the role of cyclosporin A in development of pulmonary aspergillosis, we studied the patterns of infection and inflammation in two clinically applicable rabbit models of invasive pulmonary aspergillosis. There were striking differences in the patterns of infection and inflammation of invasive pulmonary aspergillosis according to the type of underlying immune defect. Among rabbits challenged with the same intratracheal inoculum, there was a 100% mortality for invasive pulmonary aspergillosis in profoundly granulocytopenic rabbits in comparison with a 100% mortality for invasive pulmonary aspergillosis in profoundly granulocytopenic rabbits in comparison with a 100% survival in rabbits immunosuppressed with cyclosporin A plus methylprednisolone (CsA+MP). Lesions of pulmonary aspergillosis in granulocytopenic rabbits consisted predominantly of coagulative necrosis, intraalveolar hemorrhage, and scant mononuclear inflammatory infiltrate. By comparison, pulmonary foci in rabbits immunosuppressed by CsA+MP consisted mainly of neutrophilic and monocytic infiltrates, inflammatory necrosis, and scant intraalveolar hemorrhage. There was extensive infiltration by hyphae with angioinvasion in granulocytopenic rabbits, whereas conidia in various stages of germination predominated in CsA+MP treated animals in which there was a paucity of hyphae or angioinvasion. Extrapulmonary disease predominated in granulocytopenic rabbits. Methylprednisolone was the major immunosuppressive drug in rabbits treated with CsA+MP. Cyclosporin A alone did not increase the progression of pulmonary aspergillosis and did so only when used chronically with methylprednisolone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7663787     DOI: 10.1164/ajrccm.152.3.7663787

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  42 in total

1.  The pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy.

Authors:  Shane D Stephens-Romero; Aron J Mednick; Marta Feldmesser
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

2.  Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis.

Authors:  Viviane Balloy; Michel Huerre; Jean-Paul Latgé; Michel Chignard
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease.

Authors:  Carly G Dennis; William R Greco; Yseult Brun; Richard Youn; Harry K Slocum; Ralph J Bernacki; Russell Lewis; Nathan Wiederhold; Steven M Holland; Ruta Petraitiene; Thomas J Walsh; Brahm H Segal
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Andreas H Groll; Tin Sein; Robert L Schaufele; Andrea Francesconi; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

5.  N-acetylcysteine inhibits germination of conidia and growth of Aspergillus spp. and Fusarium spp.

Authors:  A J De Lucca; T J Walsh; D J Daigle
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

6.  Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis.

Authors:  Jodi M Lestner; Susan J Howard; Joanne Goodwin; Lea Gregson; Jayesh Majithiya; Thomas J Walsh; Gerard M Jensen; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

7.  Environmental monitoring for Aspergillus fumigatus in association with an immunosuppressed rabbit model of pulmonary aspergillosis.

Authors:  Kimberly A Such; Vidmantas Petraitis; Ruta Petraitiene; Gittel E Strauss; Patriss-Wais Moradi; Thomas J Walsh
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-09       Impact factor: 1.232

8.  Activation of platelets by Aspergillus fumigatus and potential role of platelets in the immunopathogenesis of Aspergillosis.

Authors:  Ernst Kristian Rødland; Thor Ueland; Turid M Pedersen; Bente Halvorsen; Fredrik Muller; Pål Aukrust; Stig S Frøland
Journal:  Infect Immun       Date:  2009-12-14       Impact factor: 3.441

9.  Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.

Authors:  V Petraitis; R Petraitiene; A H Groll; A Bell; D P Callender; T Sein; R L Schaufele; C L McMillian; J Bacher; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Development and validation of a quantitative real-time PCR assay using fluorescence resonance energy transfer technology for detection of Aspergillus fumigatus in experimental invasive pulmonary aspergillosis.

Authors:  Cathal E O'Sullivan; Miki Kasai; Andrea Francesconi; Vidmantas Petraitis; Ruta Petraitiene; Amy M Kelaher; Alia A Sarafandi; Thomas J Walsh
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.